Novel Receptor:Ligand Interactions in Osteolytic Diseases.
Pathological bone loss (osteolysis), the process whereby osteoclasts erode mineralised bone matrix, remains an unresolved challenge in the pathology of osteolytic diseases, such as osteoporosis, rheumatoid arthritis (RA) and osteolytic bone cancers. Identification of the receptors involved in osteoclast development (osteoclastogenesis) is currently a high priority in osteoclast research.
Short name and number:
NRLIOD (236932)
Name of US Partner:
UNIVERSITY OF WASHINGTON
Contact:
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (UK) / MURPHY Edna
Participating Countries:
United States
Area:
No theme specific
Category:
FP7 Project with U.S. partner
